Myriad anticipates expanding into the agricultural and veterinary sectors within the near future.
The breadth and depth of the Utah genealogy databases are major contributing factors to Myriad's scientists' success in discovering the genes for several common diseases. By using ProNet technology, the company discovers additional new genes that interact with the previous genes and other disease relevant genes in important biochemical pathways. Through the mutation screening approach, Myriad has discovered the disease associations for ten genes. A Track Record of Successful Collaborations with Pharmaceutical Companies In collaboration with major pharmaceutical companies such as Bayer, Novartis, and Schering Plough, Myriad has research programs directed to discovering genes for cancer, heart disease, obesity, asthma, osteoporosis, and central nervous system disorders such as depression and dementia. Myriad has ProNet collaborations in progress with Bayer, Schering A.G., and Pharmacia focused on a specific disease, general database access, and two specific pathways, respectively.